Qiming-backed Abbisko makes $200M+ Hong Kong debut, as a SPAC and Agenus spinout also price on Nasdaq

Max Gelman

Senior Editor

Three new entities priced their public debuts late Thursday and early Friday, including a SPAC, a traditional Nasdaq IPO and a Chinese biotech joining the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Qiming-backed Abbisko makes $200M+ Hong Kong debut, as a SPAC and Agenus spinout also price on Nasdaq

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Qim­ing-backed Ab­bisko makes $200M+ Hong Kong de­but, as a SPAC and Agenus spin­out al­so price on Nas­daq

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Qiming-backed Abbisko makes $200M+ Hong Kong debut, as a SPAC and Agenus spinout also price on Nasdaq